MOLECULAR CELLULAR BIOLOGY, Dec. 2006, p. 8683â€“8696                                                                           Vol. 26,  23
0270-7306/06/$08.00â«¹0 doi:10.1128/MCB.00940-06
Copyright Â© 2006, American Society Microbiology. Rights Reserved.



    Breast Cancer Metastasis Suppressor 1 Functions Corepressor
      Enhancing Histone Deacetylase 1-Mediated Deacetylation
                RelA/p65 Promoting ApoptosisäŒ¤â€ 
                                      Yuan Liu, Philip W. Smith, David R. Jones*
                       Department Surgery, University Virginia School Medicine, Charlottesville, Virginia
                        Received 26 2006/Returned modification 1 August 2006/Accepted 11 September 2006

             antiapoptotic transcription factor NF-â? B constitutively activated cancers important
          cytokine-mediated progression metastatic movement tumors. Breast cancer metastasis suppressor
          1 (BRMS1) metastasis suppressor gene mechanisms action poorly understood. report,
          demonstrate BRMS1 decreases transactivation potential RelA/p65 ameliorates expres-
          sion NF-â? B-regulated antiapoptotic gene products. BRMS1 immunoprecipitates RelA/p65 subunit
          NF-â? B protein-protein interactions occurring C terminus region rel homology domain           known transactivation domains.  BRMS1 functions corepressor promoting binding
          HDAC1 RelA/p65, deacetylates lysine K310 RelA/p65, suppresses RelA/p65 transcrip-
          tional activity. Selective small interfering RNA knockdown BRMS1 confirms chromatin-bound BRMS1
          required deacetylation RelA/p65, enhancing chromatin occupancy HDAC1 NF-â? B-
          regulated promoters cIAP2 Bfl-1/A1. observed cells lacking BRMS1 dramatic increase cell
          viability loss attachment extracellular matrix. Collectively, results suggest           BRMS1 suppresses metastasis ability function transcriptional corepressor antiapoptotic
          genes regulated NF-â? B.


   Aberrant constitutive activation nuclear transcrip-                cytosolic ? B, results proteasomal degradation tion factor NF-â? B detected human malignant                     subsequent liberation NF-â? B  turn, translocates
tumors (7, 14, 16, 46, 58, 61). previously shown                   nucleus, enhances transcription (4, 21). 
NF-â? B plays important role resistance non-small-                   tranuclear NF-â? B activity regulated transcriptional 
cell lung cancer (NSCLC) chemotherapy histone                            regulators function connecting sequence-specific acti-
deacetylase (HDAC) inhibition (30, 31, 41). Recently, im-                   vators basal transcriptional machinery, addition portance cytokine-mediated activation IKKâ?¤ subse-                     modifying chromatin intrinsic histone acetyl-
quently NF-â? B promotion progression inflam-                       transferase (HAT) HDAC activity (50). RelA/p65 binds matory-associated epithelial cancers identified (23,                   CBP/p300 transcriptional coactivator, p/CAF,
32, 48). Furthermore, low levels cytokine tumor necrosis                 overexpression coactivators enhances trans-
factor (TNF) produced tumor-associated macrophages                      activation potential NF-â? B (47, 56). transcriptional suggested actually increase tumor growth meta-                      activity RelA/p65 modulated HDACs,
static progression NF-â? B-dependent signaling cas-                       including HDAC-1, -2, -3, SIRT1 (2, 10, 64). Post-
cades (5, 32). Purported mechanisms NF-â? B                         translational modifications pivotal chromatin-associ-
promotes tumor progression metastatic movement include                      ated activities RelA/p65 acetylation RelA/p65 upregulation antiapoptotic gene products,                     important transcriptional activity DNA binding, proangiogenic factors (1).  increasing evidence                   impairing assembly ? Bâ?£ nuclear exporta- upregulation cell survival signals NF-â? B                  tion (11, 33). initial critical events occur metastatic                  contrast prometastatic role NF-â? B, breast cancer
process.                                                                        metastasis suppressor 1 (BRMS1) gene mapped    Transcriptionally active NF-â? B typically composed                    chromosome 11q13 originally identified metasta-
heterodimeric protein complex, best studied                    sis suppressor gene (55). BRMS1 protein product lo- common form RelA/p65/p50 heterodimer,                         calized predominantly nucleus contains imperfect
RelA/p65 contains transactivation domains. Classic activa-                  leucine zipper motif various coiled-coil domains (43, 55).
tion NF-â? B occurs IKK isoform phosphorylation                       BRMS1 mRNA expression shown markedly
                                                                                reduced melanoma breast cancer cell lines, stable
                                                                                overexpression BRMS1 cell lines significantly 
   * Corresponding author. Mailing address: Department Surgery,              hibited metastatic potential (13, 54). Interestingly, Box 800679, University Virginia, Charlottesville, VA 22908-0679.             evidence date BRMS1 regulates metastatic 
Phone: (434) 243-6443. Fax: (434) 982-1026. E-mail: djones@virginia             ment alterations matrix metalloproteinase levels,
.edu.
   â€  Supplemental material article http://mcb
                                                                                cellular adhesion profiles, alterations tumor cell invasion
.asm.org/.                                                                      (52). Recent studies indicate BRMS1 selective com-
   äŒ¤
     Published ahead print 25 September 2006.                             ponent mSin3a/HDAC corepressor complex resulting 
                                                                         8683
 8684       LIU ET AL.                                                                                                                         MOL. CELL. BIOL.


basal transcription repression measured GAL4 lucifer-                     Ac-H3(Lys9/Lys14), Ac-H4 (Lys8) (Cell Signaling Technology, Beverly,
ase reporter myelomonocytic growth factor minimal                          MA); M2 Flag-epitope tag, â?¤-tubulin, â?£-tubulin (Sigma Aldrich, St. Louis,
                                                                                  MO); HA-epitope tag (BD Biosciences, Palo Alto, CA). Acetyl-p65 (K310)
promoter (42). BRMS1 shown negatively                            antibody kindly provided Marty W. Mayo (Charlottesville, VA). Recom-
regulate nuclear translocation NF-â? B urokinase-                        binant TNF purchased Sigma (St. Louis, MO). TNT T7 Quick-
type plasminogen activator transcripts processes                       Coupled transcription/translation obtained Promega Bio-
volving inhibition ? Bâ?£ phosphorylation (13).                                  sciences (San Luis Obispo, CA).
                                                                                     Total RNA isolation, quantitative reverse transcriptase PCR (RT-PCR),    Given BRMS1 functions metastasis suppressor                                                                                   NF-â? B-regulated gene expression assays. Total RNA extracted using associated known corepressor complex                          TRIzol (Invitrogen) according manufacturerâ€™s protocol. brief, 106 cells NF-â? B activation associated development                       100 mg tissue lysed 1 ml TRIzol, proteins metastases, sought determine BRMS1                           separated chloroform. RNAs precipitated isopropanol, cDNAs
regulating NF-â? B transcriptional activity effects                      synthesized using Advantage RT PCR enzyme kit (Clontech, Palo
                                                                                  Alto, CA). BRMS1 expression determined real-time PCR iCycler
RelA/p65 acetylation. Using NSCLC model                              IQ (Bio-Rad, Hercules, CA). human BRMS1 primers TGCAGCGG
demonstrate BRMS1 represses basal induc-                        AGCCTCAAG (forward) TCACATCCAGACAGAAGCCCT (reverse).
ible transactivation potential RelA/p65 functioning                    Human HPRT gene amplified reference gene (38). Real-time PCR
corepressor HDAC1 addition decreasing HDAC1                             quantification processed. expression BRMS1 (âŒ¬TC) normalized
binding RelA/p65. Using site-directed mutagenesis se-                      endogenous reference gene (HPRT) (TCR). âŒ¬TC value calculated
                                                                                  subtracting TC value reference (TCR) TC value lective small interfering RNA (siRNA) knockdown specific                       sample (TCS): âŒ¬TC â«½ TCS â«º TCR. relative expression (2âŒ¬âŒ¬TC) calibrator
HDACs, identified BRMS1/HDAC1 core-                              (placenta RNA; Clontech, Palo Alto, CA) determined subtracting pressor complex reduces NF-â? B-dependent transcription                     âŒ¬TCC (calibrator, âŒ¬TCC â«½ TCCS â«º TCCR) âŒ¬TC value (âŒ¬âŒ¬TC â«½
deacetylation RelA/p65 lysine K310. Futhermore, siRNA                       âŒ¬TCC (calibrator) â«º âŒ¬TC).
                                                                                     NF-â? B-regulated gene expression assays, HEK 293T cells H1299 cells
knockdown BRMS1 recruits endogenous acetyl-K310-RelA/
                                                                                  plated 24 h transfection. BRMS1 overexpression assays, BRMS1
p65 chromatin NF-â? B-dependent antiapoptotic genes                       expression vector vector control transiently transfected cIAP2 Bfl-1/A1 promoters simultaneously inhibiting                      using Polyfect reagent (QIAGEN, Valencia, CA) according manufactur-
endogenous HDAC-1 chromatin occupancy. Finally, using                          erâ€™s instructions. BRMS1 knockdown assay, siRNA BRMS1 siRNA 
anoikis cell model metastasis, demonstrate BRMS1                       trol (100 nM) transfected using Oligofectamine (Invitrogen, Carlsbad,
                                                                                  CA) according manufacturerâ€™s instructions. day transfection, significantly increases apoptosis suspended NSCLC cells                        additional 100 nM siRNA transfected H1299 cells described  cytokine stimulation.                                                       36 h transfection, TNF (10 ng/ml) added cells    Collectively, results indicate BRMS1 functions                   additional 12 h. Total RNA extracted using TRIzol, followed real-time corepressor modulates NF-â? B-dependent antiapoptotic                        RT-PCR described  PCR primers used follows: cIAP-2,                                                                                   5â¬˜-GCTGTGATGGTGGACTCAGG-3â¬˜ (forward) 5â¬˜-TGGCTTGAACTT
transcription chromatin level. observations sug-
                                                                                  GACGGATG-3â¬˜ (reverse); Bfl-1/A1, 5â¬˜-TCATATTTTGTTGCGGAGTTCA-3â¬˜
gest BRMS1 expression prevent metastases                          (forward) 5â¬˜-TCCAGCCAGATTTAGGTTCAAA-3â¬˜ (reverse); Bcl-xL,
ability corepressor regulate NF-â? B transcription                   5â¬˜-GCATTGTGGCCTTTTTCTCC-3â¬˜ (forward) 5â¬˜-GCTGCTGCATTGTT
cell survival loss cellular adhesion.                                CCCATA-3â¬˜ (reverse); VCAM-1, 5â¬˜-GCTGCTCAGATTGGAGACTCA-3â¬˜
                                                                                  (forward) 5â¬˜-CGCTCAGAGGGCTGTCTATC-3â¬˜ (reverse); ICAM-1, 5â¬˜-C
                                                                                  TGTGTCCCCCTCAAAAGTC-3â¬˜ (forward) 5â¬˜-GGGGTCTCTATGCCCA
                       MATERIALS METHODS                                      ACAA-3â¬˜ (reverse); E-Selectin, 5â¬˜-TGAAGCTCCCACTGAGTCCAA-3â¬˜  
   Cell culture, surgical specimens, reagents, plasmid constructs. Human      ward) 5â¬˜-GGTGCTAATGTCAGGAGGGAGA-3â¬˜ (reverse); GAPDH,
NSCLC lines (NCI-H157, NCI-H358, NCI-H460, NCI-A549, NCI-H1299),            5â¬˜-CTACACCTTGCCTGTGAGCA-3â¬˜ (forward) 5â¬˜-GACACGTGTGGCC
normal human bronchial epithelial cell line (NL-20), tumorigenic non-     ATTGTAG-3â¬˜ (reverse).
metastatic human embryonic kidney cells (HEK 293T) (63) obtained           Transfection luciferase reporter assays. Plasmids reporters American Type Culture Collection (Manassas, VA). NSCLC cell lines         transiently cotransfected cells 40 60  confluence using Polyfect
HEK 293T cells grown described previously (64). NL20 cells           reagent described  Luciferase reporter activity assays performed cultured Ham F-12 medium (Invitrogen, Carlsbad, CA) supplements           previously described (41). â?¤-Galactosidase activities analyzed control according manufacturerâ€™s protocol. Human NSCLC specimens adja-         efficiency transfection. Luminescence normalized protein concen-
cent noncancerous lung preserved according standard surgical resection    trations, transfection data means â«¾ standard deviations (SD) patients Division Thoracic Surgery, University Virginia,   independent experiments performed triplicate analyses. informed consent Human Investigations Committee approval.               Immunoprecipitation Western blot. HEK 293T cells transfected 3x-â? B luciferase reporter (3x-â? B-Luc), Gal-4 luciferase construct (Gal4-Luc),     expression vectors encoding Flag-tagged p65, HA-tagged BRMS1,  Cells
expression vectors encoding Gal4-p65 fusion protein (1-286, 286-520, 286-551,     harvested 48 h transfection. select experiments, HEK 293T cells
520-551, 1-551, 286-551/K310R), expression vectors (pGEX) encoding GST-       transfected siRNA BRMS1 control. immunoprecipitation 
p65 fusion proteins (1-305, 245-455, 354-551), plasmids (pCMV) encod-     says, primary antibody (2 â?®g anti-HA-epitope tag, 3.4 â?®g anti-Flag-epitope
ing Flag-tagged p65 previously described (41, 51, 64). Human BRMS1           tag, 3.1 â?®g anti-â?¤-tubulin, 4 â?®g anti-myc, 4 â?®g anti-p65, 4 â?®g cDNA cloned PCR  primers 5â¬˜-GTATGAATTCGACCTGTC                    anti-BRMS1, 4 â?®g anti-HDAC1, 4 â?®g anti-HDAC3) mixed CAGCCTCCAAGC-3â¬˜ [forward] 5â¬˜-GTATCTCGAGTCAAGGTCCATCC                          precleared cell lysates hour 4Â°C addition 30 â?®l protein
GATTTTC-3â¬˜ [reverse]; restriction sites underlined) inserted     agarose G (Santa Cruz, Santa Cruz, CA), reactions tumbled 
hemagglutinin (HA)-tagged pCMV vector (Clontech, Palo Alto, CA)               night 4Â°C. agarose beads extensively washed, eluted protein
pcDNA3.1(â«¹) vectors (Invitrogen, Carlsbad, CA) using restriction enzymes      resolved sodium dodecyl sulfate-polyacrylamide gel electrophoresis
EcoRI XhoI (New England Biolabs, Beverly, MA). Human HDAC1                (SDS-PAGE), followed immunoblot analysis. Western blots 
cloned PCR  HDAC1 primers 5â¬˜-CGGAATTCACGATGGCGCA                      formed according standard procedures. Proteins separated SDSâ€“
GACGCAGGGCAC-3â¬˜ [forward] 5â¬˜-CGGAATTCGGCCAACTTGACCT                           12  PAGE. transfer, nitrocellulose membranes (Bio-Rad, Hercules,
CCTCCTTG-3â¬˜ [reverse]) inserted pcDNA3.1(â«¹) vectors using EcoRI          CA) probed primary antibodies 1:1,000 dilution secondary
sites. siRNA SMART pool human BRMS1, HDAC1, HDAC3, siCONTROL                  antibodies (Promega, Madison, WI) 1:5,000 dilution blocking solution.
nontargeting siRNA purchased Dharmacon (Chicago, . anti-         Proteins visualized enhanced chemiluminescent substrate (Pierce
bodies used present study follows: BRMS1 (Abnova Corp., Tai-       Biotechnology, Rockford, .
wan); RelA/p65, mSin3A, p300, myc, normal rabbit immunoglobulin G (IgG;          GST binding assays. Glutathione S-transferase (GST)â€“p65 fusion proteins
Santa Cruz Biotechnology, Santa Cruz, CA); â?£-acetyl-lysine, HDAC1, HDAC3,         expressed Escherichia coli BL21 (Amersham, Piscataway, NJ) puri-
 VOL. 26, 2006                                                                                                                BRMS1 NF-â? B            8685

fied described previously (18). relative abundance fusion protein GST evaluated using SDSâ€“10  PAGE gel stained Coomassie
blue. pcDNA3.1(â«¹)-BRMS1 expression vector translated TNT
reticulocyte binding 35S-labeled methionine (Amersham, Piscataway,
NJ) according manufacturerâ€™s protocol. Labeled BRMS1 rocked 2 h room temperature GST-p65 fusion proteins total volume 500
â?®l NETN buffer (20 mM Tris-HCl [pH 7.5], 100 mM KCl, 0.7 mM EDTA,
0.05  Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride). reactions extensively washed NETN buffer, bound proteins resolved 15  denaturing SDS-PAGE gels analysis autoradiography.
   RelA/p65 deacetylation assays. RelA/p65 deacetylation assays performed previously described (11). HEK 293T cells transfected expression
vector encoding HA-tagged BRMS1 vector. select experiments, cells cotransfected siRNA HDAC1, HDAC3, siRNA control 
scribed  treatment TNF (0, 20, 40 ng/ml) 1 h, cell lysates resolved SDS-PAGE gels immunoblotted specific acetyl-
p65(K310) antibody. vitro deacetylation assays, HEK 293T cells cotransfected expression vectors encoding Flag-tagged p65 p300. Cell lysates immunoprecipitated 4 â?®g Flag antibody. RelA/
p65 deacetylation assays performed incubating 20 â?®l immunoprecipi-
tated Flag-RelA/p65 protein 10 â?®l vitro-translated BRMS1 protein increasing amounts HDAC1 protein using TNT reticulocyte HDAC buffer (10 mM Tris-HCl [pH 8.0], 10 mM NaCl, 10  glycerol) 2 h room temperature. reactions washed times HDAC
buffer analyzed immunoblotting pan-acetyl-lysine antibody.
   Caspase-3, DNA fragmentation, cell death assays. HEK 293T cells H1299 cells transiently transfected pCMV-BRMS1 expression vector vector control. Cells left untreated treated TNF (50
ng/ml) 24 h transfection. 48 h posttransfection, apoptosis quantified quantitation nucleosomes released cytoplasm using cell death
detection ELISA Plus kit (Roche Applied Science) according manufac-
turerâ€™s directions. Caspase-3 activity determined addition APC-
DEVD protein conjugate (Calbiochem, San Diego, CA) cellular extracts
containing 30 â?®g protein. fluorescence caspase-3-cleaved protein 
jugates measured. cell death assays, BRMS1 overexpressed transfecting pCMV-BRMS1 expression vector vector control suppressed transfecting siRNA BRMS1 siRNA control HEK 293T H1299 cells described  48 h transfection, cells suspended,
respectively, 0, 0.5, 1, 2, 3 h. Cells replated, percentage cell death obtained enumerating trypan blue-positive cells versus total number cells additional 24 h incubation.
   ChIP. overexpression experiments, HEK 293T cells transfected pCMV-BRMS1 vector. RNA interference experiments, HEK 293T
cells transfected siRNA BRMS1 siRNA control described  36 h, cells left untreated treated TNF (10 ng/ml) additional 12 h. Chromatin immunoprecipitation (ChIP) assays 
formed described previously (34). DNA immunoprecipitated 4 â?®l antibody (anti-BRMS1, anti-p65, anti-p50, anti-mSin3A, anti-acetyl-p65 K310,              FIG. 1. BRMS1 expression reduced NSCLC cells tumor
anti-HDAC1, anti-HDAC3, Ac-H3, Ac-H4, normal rabbit IgG) purified.              tissues.   BRMS1 mRNA protein expression tumorigenic regions human cIAP-2 Bfl-1/A1 promoters containing â? B binding           nonmetastatic cell lines (NL20 HEK 293T) NSCLC cell lines
sites targeted amplification described previously (38). PCR data      (H358, H1299, H157, A549, H460). mRNA levels evaluated
analyzed previously described (8).                                                  quantitative RT-PCR calculated ratio human pla-
   Statistical analysis. results experiments represent means â«¾      centa control  . Protein levels BRMS1 detected West-
SD separate experiments performed triplicate unless noted.       ern blotting â?£-tubulin loading control  . Real-time
Statistical differences control BRMS1 groups determined          RT-PCR data represent mean â«¾ SD experiments tailed, unpaired Student t test appropriate. P values â¬?0.05           performed triplicate. (B) BRMS1 mRNA protein expression considered significant.                                                                tumor tissues patient-matched adjacent lung tissues. mRNA                                                                                        protein levels patient-matched samples determined                                                                                        panel  pathological stage presented using international
                                  RESULTS                                              staging lung cancer (44). Stage IA NSCLC limited local
                                                                                       disease metastasis lymph nodes. Stage IIB NSCLC includes
   BRMS1 expression decreased NSCLC. NSCLC                                  spread local lymph nodes. Stage IIIB disease includes metastasis highly malignant cancer proclivity metastasizing                         regional lymph nodes outside lung itself. lymph nodes distant organs. BRMS1 sup-
pressor metastasis, suggests aggressiveness NSCLC related intratumoral BRMS1 levels.                              NSCLC cell lines examined. Parallel results shown test hypothesis, BRMS1 mRNA protein expression                                BRMS1 protein expression (Fig. 1A).
levels determined different human NSCLC cell                                determine expression pattern lines real-time RT-PCR immunoblotting. Compared                              present surgically resected human NSCLC adjacent immortalized bronchial epithelial NL20 HEK293T                                 noncancerous lung tissue, BRMS1 mRNA protein levels
cells, BRMS1 mRNA levels markedly decreased                                 detected using techniques. shown Fig.
 8686      LIU ET AL.                                                                                                              MOL. CELL. BIOL.




   FIG. 2. BRMS1 inhibits constitutive TNF-induced NF-â? B transcriptional activity NF-â? B-dependent gene expression.   293T H1299 cells transiently cotransfected NF-â? B-responsive reporter (3x-â? B-Luc) mutant 3x-â? B-Luc reporter expression vector
encoding BRMS1. 18 h transfection cells treated treated TNF (10 ng/ml) 12 h. luciferase activity determined. transfections normalized cytomegalovirus (CMV)â€“â?¤-galactosidase activity. (B) 293T cells H1299 cells transiently cotransfected Gal4-Luc reporter expression vector encoding fusion protein Gal-4-p65 BRMS1. 18 h transfection cells treated treated TNF (10 ng/ml) 12 h. luciferase activity determined. transfections normalized CMVâ€“â?¤-galactosidase activity. (C) 293T cells transiently transfected BRMS1 CMV-driven vector (Control).
Cells treated treated TNF (10 ng/ml) 12 h. Total RNA extracted, NF-â? B regulated antiapoptotic gene mRNA
levels analyzed quantitative RT-PCR. data plotted fold control, results cells transfected control
vector normalized 1 gene. ##, P â¬? 0.01 compared control; â´±â´±, P â¬? 0.01 compared control â«¹ TNF. (D) 293T cells  VOL. 26, 2006                                                                                                  BRMS1 NF-â? B            8687


1B, expression BRMS1 mRNA protein decreased                    BRMS1 coimmunoprecipitates RelA/p65 p50 nearly tumor tissues compared adjacent non-              subunits NF-â? B. determined BRMS1
cancerous tissues. Interestingly, reduction                coimmunoprecipitate components NF-â? B BRMS1 protein mRNA levels patient (patient                 known antiapoptotic function, RelA/p65 p50.
4) early-stage disease.  BRMS1 expression               Exogenous RelA/p65 BRMS1 reciprocally immuno- NSCLC cell lines tumor tissues markedly decreased             precipitated overexpression HA-tagged BRMS1
compared noncancerous cells tissues, suggesting               Flag-tagged RelA/p65 (Fig. 3A). negative control, development progression NSCLC involve                  â?¤-tubulin monoclonal antibody, myc polyclonal antibody
loss BRMS1 expression.                                                 failed detect immunoprecipitation protein complexes,
   BRMS1 represses transactivation potential RelA/p65.             confirming specificity anti-Flag anti-HA anti-
Previous studies indicated nuclear translocation            bodies, respectively. coimmunoprecipitation DNA-binding activity NF-â? B suppressed breast                 BRMS1 RelA/p65 occurred overexpression 
cancer MDA-MB-231 melanoma C8161.9 cell lines                    says, wanted determine proteins
stably overexpress BRMS1 (13). determine                       interact similar fashion endogenously. shown BRMS1 abolish NF-â? B transcriptional activity                 reciprocal coimmunoprecipitation assays Fig. 3B, endog-  transient-transfection 3x-â? B luciferase assays           enous BRMS1 nuclear extracts does coimmunoprecipitate
formed treatment TNF. chose TNF stimulus               endogenous RelA/p65 p50. association
based ability enhance metastatic progression epi-           BRMS1 nuclear RelA/p65 p50 subunits
thelial cancers NF-â? B-dependent manner (32). shown               NF-â? B implies BRMS1 affect NF-â? B transcription Fig. 2A, BRMS1 dramatically diminished basal TNF-                  directly interacting RelA/p65-p50 heterodimer.
induced NF-â? B transcriptional activity cell lines. Fail-             BRMS1 directly binds RelA/p65 subunit NF-â? B.
ure BRMS1 affect transcription cells expressing                RelA/p65 contains N-terminal Rel homology domain
mutant 3x-â? B-Luc reporter gene confirms NF-â? B specificity.                (RHD) consisting approximately 286 amino acids Given BRMS1 shown affect NF-â? B                   mediates DNA binding dimerization (22). transac-
decreased cytosolic ? B processing (13), sought specifi-            tivation domains present C terminus region RelA/
cally examine ability BRMS1 regulate transacti-             p65, regulate interaction NF-â? B various
vation potential RelA/p65  accomplish  Gal4/              basal transcriptional components associates p65-Luc reporter gene assays performed (Fig. 2B).              p300/CBP transcriptional coactivators (3, 20, 22, 47, 56). demonstrated BRMS1 significantly represses transac-              characterize protein binding domains tivation potential RelA/p65 TNF stimulation.                     BRMS1 RelA/p65, performed GST pull assays.
   order determine BRMS1 decrease                GST truncated GST-RelA/p65 fusion proteins (Fig. 3C) expression classic NF-â? B-dependent antiapoptotic genes             used examine interaction BRMS1 (cIAP-2, Bfl-1/A1, BclxL) (9, 60, 67), 293T cells trans-         vitro rabbit reticulocyte transcription/translation  fected expression vector encoding BRMS1 quantita-                shown Fig. 3D, BRMS1 strongly bind GST-
tive RT-PCR performed (Fig. 2C). BRMS1 significantly                  RelA/p65(245-455) fusion protein modestly interact
decreased TNF-induced cIAP-2, Bfl-1/A1, Bcl-xL tran-                  GST-RelA/p65(1-305) fusion protein GST
scripts. determine BRMS1 decreased                  GST-RelA/p65(354-551) construct. sug-
NF-â? B-regulated genes known involved metastasis,                 gests region RelA/p65 directly interacts RT-PCR experiments repeated intracellular ad-                BRMS1 primarily located amino acids 245 354
hesion proteins ICAM, VCAM, E-selectin (36, 37, 59).               RelA/p65. region corresponds C-terminal end shown Fig. 2D, significant effect BRMS1                RHD does include transactivation domains overexpression transcripts, effect          RelA/p65.
non-NF-â? B regulated gene GAPDH. confirm regula-                      determine correlation tion NF-â? B-regulated antiapoptotic genes specific                BRMS1-binding regions RelA/p65 protein BRMS1, selective silencing BRMS1 expression using siRNA                transactivation potential RelA/p65, Gal4/p65 constructs
resulted robust rescue antiapoptotic genes           ectopically expressed 293T  Gal4/
(Fig. 2E). results indicate BRMS1 inhibits                 p65 luciferase activity determined presence ab-
transactivation potential RelA/p65 establishes           sence BRMS1. Maximal BRMS1-mediated repression evidence BRMS1 modulate cancer cell survival                     RelA/p65 transactivation occurred cells overexpressing transcriptional repression NF-â? B-regulated anti-               Gal4-RelA/p65(286-551) Gal4-RelA/p65(286-520) pro-
apoptotic genes.                                                          teins (Fig. 3E). BRMS1 little ability repress




transiently transfected BRMS1- CMV-driven vector (control). Cells treated treated TNF (10 ng/ml) 12 h. Total
RNA extracted, NF-â? B regulated gene housekeeping gene (GAPDH) mRNA levels analyzed quantitative RT-PCR. data analyzed described  statistical difference control BRMS1 groups. (E) 293T cells H1299 cells transiently transfected siRNA BRMS1 siRNA control. Cells treated treated TNF (10 ng/ml) 12 h. total RNA extracted, NF-â? B regulated antiapoptotic gene mRNA levels analyzed quantitative RT-PCR. data plotted described panel C. Western blots cell lysates effective knockdown siRNA â?£-tubulin loading control.
 8688     LIU ET AL.                                                                                                         MOL. CELL. BIOL.




   FIG. 3. BRMS1 colocalizes RelA/p65 p50 subunits directly interacts RelA/p65 subunit NF-â? B.   293T cells cotransfected expression vector encoding HA-tagged BRMS1, Flag-tagged RelA/p65,  Cell lysates immunoprecipitated Flag
polyclonal antibody HA monoclonal antibody, followed immunoblotting presence BRMS1 RelA/p65, respectively. Input protein
showed relatively equal amounts HA-tagged BRMS1 Flag-tagged RelA/p65 expressed immunoprecipitated. cell
lysates immunoprecipitated â?¤-tubulin monoclonal antibody myc polyclonal antibody, respectively, controls nonspecific
interference antibody. (B) 293T cell isolated nuclear lysates coimmunoprecipitated negative control (IgG) antibody BRMS1,
RelA/p65, p50, followed immunoblotting presence endogenous RelA/p65, p50, BRMS1. Input protein showed relatively
equal amounts endogenous, RelA/p65, p50, BRMS1 expressed immunoprecipitated. (C) Schematic illustration RelA/p65
proteins. 1-551 construct encodes length Rel/p65 protein. RHD, Rel homology domain (u); TAD, transactivation domains (o). (D) vitro-translated [35S]methionine-labeled BRMS1 incubated GST-RelA/p65 fusion proteins (1-305, 245-455, 354-551) GST (negative control). Proteins retained GST GST-RelA/p65 fusion proteins eluted analyzed SDS-PAGE autoradiography
(n â«½ 3)  . GST-RelA/p65 fusion proteins separated SDSâ€“15  PAGE gel stained Coomassie blue indicating relative
amounts GST fusion protein. (E) 293T cells transiently cotransfected Gal4-Luc reporter expression vector encoding
Gal4-RelA/p65 fusion proteins (1-286, 286-520, 286-551, 520-551, 1-551). addition, cells transfected expression vector
encoding BRMS1 vector (control). transfections normalized CMVâ€“â?¤-galactosidase activity. fold repression calculated basal transcription values Gal4-RelA/p65 vector normalized 1. Western blot analysis confirms expression various Gal4-p65 fusion proteins.




RelA/p65 transactivation N-terminus C-terminus                   BRMS1 deacetylates RelA/p65 lysine residue 310. regions protein. Collectively, data suggest            transactivation potential RelA/p65 regulated BRMS1-mediated repression transactivation potential               reversible acetylation (11, 64). RelA/p65 pro- RelA/p65 result direct binding            tein known acetylated lysine (K) residues, 122, proteins region located amino acids               123, 218, 221, 310. K310 known important
245 354 RelA/p65.                                                 transactivation function RelA/p65 (33, 64).
 VOL. 26, 2006                                                                                                         BRMS1 NF-â? B             8689




  FIG. 4. BRMS1 abolishes TNF-induced NF-â? B acetylation lysine 310.   293T cells cotransfected expression plasmid encoding
HA-tagged BRMS1 vector control. 48 h posttransfection, cells treated TNF 1 h indicated concentrations. Western
blots cell lysates demonstrate acetylation lysine 310 p65 using specific acetyl-p65(K310) antibody relatively constant total p65. blots confirmed expression HA-BRMS1 â?£-tubulin loading control. (B) 293T H1299 cells transiently transfected Gal4-Luc reporter plasmid encoding Gal4-p65 fusion protein (286-551) mutant Gal4-p65 fusion protein (286-551, K310R). addition, plasmid encoding BRMS1 vector (control) cotransfected indicated. 18 h transfection, cells treated treated TNF (10 ng/ml) 12 h. luciferase activity determined. transfections normalized CMVâ€“â?¤-galactosidase
activity. fold repression calculated basal transcription values Gal4-RelA/p65 vector K310R mutant vector normalized 1. Western blot analysis confirmed expression various Gal4-p65 fusion proteins.




Based data point, hypothesized                       BRMS1 functions corepressor RelA/p65 deacetyla-
BRMS1 repress transactivation potential RelA/p65                   tion. determine class HDACs primarily respon- modulation acetylation state. Using anti-acetyl                 sible BRMS1-mediated deacetylation RelA/p65, 3x-â? B
RelA/p65 K310 antibody, deacetylation assays performed                   luciferase assays repeated presence HDAC endogenous RelA/p65 acetylated K310                     inhibitors. Trichostatin (TSA) typical inhibitor class dose-dependent manner stimulation TNF. Impor-                   II HDACs class III (40). Nicotinamide (NAM) tantly, addition BRMS1 effectively deacetylated RelA/                  specific negative regulator class III HDACs (6). TSA signif-
p65 K310 despite escalating doses TNF (Fig. 4A).                        icantly rescued BRMS1 repression basal TNF-induced
   investigated deacetylation RelA/p65                     NF-â? B-dependent transcription, NAM did (Fig. 5A).
K310 important target BRMS1-mediated repression                      inhibition class II HDACs, class III, RelA/p65 activity. shown Fig. 4B, ectopic expression              involved BRMS1-mediated deacetylation RelA/p65.
BRMS1 dramatically reduced basal TNF-induced                           Previous studies reported BRMS1 forms com-
RelA/p65 transactivation potential, supporting prior ex-                  plexes retinoblastoma-binding protein 1 mSin3A
periments (Fig. 2A B). addition, overexpression                   histone deacetylase complex (42), corepressor
site-directed mutant Gal4-p65 (K310R) fusion protein                   function mSin3A derived associations HDAC1 resulted ca. 50  repression RelA/p65 transactivation                -2 (24, 35, 45). addition, HDAC3 known deacetylate
potential compared wild-type constructs, finding             RelA/p65 (10, 33) interactions corepres- agreement prior reports (11). Importantly, transient                  sors NCoR SMRT (25, 26). Coimmunoprecipitation assays
transfection BRMS1 failed repress basal                    performed identify HDAC interacted TNF-induced transactivation potential RelA/p65 af-                     BRMS1. HDAC1, HDAC3, associated
ter loss lysine K310 (Fig. 4B). data strongly                    endogenous BRMS1 (Fig. 5B). Understanding suggest deacetylation K310 RelA/p65 required                    BRMS1 corepressor function, sought deter- BRMS1-mediated repression transactivation po-                      BRMS1 affect binding HDAC1 tential RelA/p65.                                                          RelA/p65. shown Fig. 5C, siRNA BRMS1 dramatically
 8690     LIU ET AL.                                                                                                           MOL. CELL. BIOL.




   FIG. 5. HDAC1 required BRMS1-mediated RelA/p65 deacetylation.   293T H1299 cells transiently cotransfected 3x-â? B-Luc reporter plasmid encoding BRMS1 vector control. 18 h transfection, cells treated treated TSA
(500 nM) NAM (500 â?®M) additional 12 h. Cells simultaneously treated treated TNF (10 ng/ml). luciferase activity determined. transfections normalized CMVâ€“â?¤-galactosidase activity. data represent typical experiment performed duplicate, means â«¾ SD. (B) 293T cell lysates coimmunoprecipitated control (IgG), anti-HDAC1, anti-HDAC3
antibody, followed immunoblotting presence endogenous BRMS1. Input protein showed relatively equal amounts endogenous
BRMS1, HDAC1, HDAC3 expressed immunoprecipitated. (C) 293T cells transfected siRNA BRMS1 siRNA control. Cell
lysates coimmunoprecipitated anti-p65, presence endogenous HDAC1 probed Western blotting. (D) 293T cells transfected expression vector encoding Flag-tagged RelA/p65 HA-tagged p300. Cell lysates immunoprecipitated anti-Flag antibody. left, pellets incubated rabbit reticulocyte (lane 3), vitro-translated HDAC1 (10 â?®l)   VOL. 26, 2006                                                                                                       BRMS1 NF-â? B             8691


decreases binding HDAC1 RelA/p65, suggesting                      NSCLC cells. H1299 cells chosen BRMS1 required process.                                          reduced BRMS1 expression relative 293T cells.    demonstrated BRMS1 abolishes                        putative NF-â? B binding sites identified cIAP-2
acetylation RelA/p65 K310, unclear                  promoter positions â«º147, â«º197, â«º210 putative
deacetylation histone deacetylases known associate              NF-â? B binding element Bfl-1/A1 promoter position â«º823 BRMS1  alternatively, BRMS1 itself                    (15, 27). noted previously, unrelated downstream sequences
trinsic deacetylase activity. experimentally address                 genes amplified control  Fig. S1 question, RelA/p65 acetylated using p300 vivo               supplemental material). incubated vitro translated BRMS1, increasing                       shown Fig. 6A B, RNA interference inhibition doses HDAC1,  addition BRMS1 protein                       BRMS1 dramatically increases TNF-mediated endogenous unable deacetylate RelA/p65. HDAC1 pro-                   acetylation RelA/p65 (K310) chromatin demonstrated
duced modest deacetylation RelA/p65,                      using specific anti-K310 antibody. addition, selective
recombinant proteins added, significant deacetylation                silencing BRMS1 concomitantly decreases chromatin occu-
RelA/p65 observed (Fig. 5D). confirm requirement                  pancy HDAC1 affecting HDAC3 loading. oc- BRMS1 deacetylating RelA/p65, vitro deacety-                 curs cIAP2 Bfl-1/A1 promoters. 
lation assays repeated increasing doses HDAC1                   trast, ectopic expression BRMS1 resulted enhanced BRMS1, modest deacetylation                        recruitment HDAC1 promoters significant
observed (Fig. 5D). results indicate BRMS1                  reduction acetylated RelA/p65 (Fig. 6C). Interestingly,
does possess intrinsic HDAC activity;  ex-                  RelA/p65 chromatin loading increased ectopic ex-
pressed HDAC1, effectively deacetylate                    pression silencing BRMS1, suggesting BRMS1 does
RelA/p65.                                                                    govern basal inducible loading RelA/p65 chroma-
   order confirm ability BRMS1 deacetylate              tin. corepressor, BRMS1 function
RelA/p65 binding HDAC1, used RNA                          global regulator chromatin structure, evidenced
interference separately knockdown HDAC1 HDAC3 ex-                      ability decrease promoter occupancy Ac-H3 pression presence BRMS1. shown Fig. 5E,                      Ac-H4 cIAP2 Bfl-1/A1 promoters. selective HDAC1 knockdown presence BRMS1                        ChIP findings cell type specific similar results
sulted partial rescue endogenous RelA/p65 acetylation                observed H1299 NSCLC cells  Fig. S2 (compare lanes 10 11), HDAC3 knockdown did                       supplemental material).
(compare lanes 10 12). similar experimental design,                    data provide compelling evidence BRMS1 transcriptional activity NF-â? B partially rescued            required corepressor regulates NF-â? B transcription loss HDAC1 presence BRMS1 overex-                      modulating acetylation status RelA/p65 HDAC1-
pression demonstrable rescue following HDAC3                         dependent manner.
knockdown (Fig. 5F). Interestingly, deacetylation (Fig.                 Modulation BRMS1 expression sensitizes cells TNF-
5E) NF-â? B transcriptional activity assays (Fig. 5F), knock-              induced apoptosis. Understanding importance TNF- HDAC1 unable completely abolish BRMS1-                        mediated tumor growth (32, 48) observation mediated RelA/p65 deacetylation repression NF-â? B tran-                 ectopic expression BRMS1 inhibits NF-â? B-dependent anti-
scriptional activity, suggesting HDACs                  apoptotic gene expression, hypothesized BRMS1 tether BRMS1. Despite results, data presented                 sensitize cancer cells apoptotic cell death. exper-
indicate BRMS1/HDAC1 complex functions regu-                     imentally address hypothesis, apoptosis assays 
late deacetylation RelA/p65.                                          formed 293T cells H1299 NSCLC cells transiently
   Silencing chromatin-bound BRMS1 promotes acetylation                   overexpressed BRMS1. shown Fig. 7A B, BRMS1 RelA/p65 decreases HDAC1 loading NF-â? B-depen-                      overexpression sensitized cells TNF-induced apoptosis, dent promoters. elucidate direct cor-                 indicated enhanced DNA fragmentation caspase-3 ac-
relation BRMS1 deacetylation RelA/p65                      tivity, respectively.
pression NF-â? B mediated transcription, ChIP assays                      detachment cellular matrix, suspended 
performed promoter NF-â? B-regulated anti-                   mal endothelial epithelial cells enter programmed cell
apoptotic cIAP-2 Bfl-1/A1 genes 293T H1299                    death, process known anoikis (19). Oncogenic transfor-




BRMS1 (10 â?®l) plus increasing doses HDAC1 (0, 1, 5, 10, 15 â?®l). right, pellets incubated rabbit reticulocyte (lane 3) increasing doses vitro-translated HDAC1 (0, 1, 5, 10, 15 â?®l). pan-acetyl-lysine antibody probed immunoblotting.
RelA/p65 control detected equal amounts RelA/p65 IP. (E) 293T cells transfected expression vector encoding
HA-tagged BRMS1or vector control. addition, siRNA HDAC1, siRNA HDAC3, siRNA control cotransfected indicated. 48 h transfection, cells treated treated TNF (20 ng/ml) 1 h. Western blots cell lysates showed relative
differences acetylation K310 p65 using specific acetyl-p65(K310) antibody relatively constant levels total p65 protein. Western blots HDAC1 HDAC3 effective knockdown siRNA. Western blot HA shows expression HA-BRMS1 tubulin loading control. (F) 293T cells transiently cotransfected 3x-â? B-Luc reporter plasmid encoding BRMS1 vector control. Cells cotransfected siRNA HDAC1, siRNA HDAC3, siRNA control. Cells treated treated TNF (10 ng/ml) 12 h harvesting luciferase activity assays. transfections normalized CMVâ€“â?¤-galactosidase activity. Western blots indicate siRNA HDAC1 HDAC3 specifically knocks protein expression.
 8692     LIU ET AL.                                                                                                        MOL. CELL. BIOL.




   FIG. 6. BRMS1 potentiates recruitment HDAC1 diminishes chromatin-associated acetyl-p65 specific K310 cIAP-2 Bfl-1/A1 promoters.   Western blots indicate siRNA BRMS1 specifically knocks BRMS1 expression. (B) 293T cells transfected siRNA BRMS1 siRNA control (siControl). Cells treated TNF (10 ng/ml) 12 h harvesting. ChIP analysis performed previously described antibodies. Chromatin-associated protein complexes assessed quantitative PCR using PCR
primers specific cIAP-2 Bfl-1/A1 promoters. fold expression calculated amplified promoter fragment treatment normalized 1. results represent means â«¾ SD separate experiments performed triplicate. (C) Similar
experiments repeated described  exception expression vector encoding BRMS1 vector (Control) ectopically expressed transient transfection instead siRNA.



mation known result ability cells survive          mediated loss BRMS1 expression 
suspension. ability cancer cells evade anoikis             creased tumor cell apoptosis anoikis, potentially resulting required development metastatic disease. deter-            larger number viable cells implantation meta- relative contribution BRMS1 anoikis, cell               static site.
model tumor cells suspension created. shown Fig. 7C, 293T H1299 cells transiently expressing BRMS1                                         DISCUSSION significantly cell death longer sus-
pension compared controls. Conversely, siRNA knockdown                 order explore signal transduction pathways related BRMS1 resulted little cell death despite detached            BRMS1 NF-â? B, chose examine lung cancer cell 3 h. suggests mechanism metastasis             model lung cancer highly metastatic disease
    FIG. 7. BRMS1 sensitizes NSCLC cells apoptosis.   293T cells H1299 cells transiently transfected expression vector
encoding BRMS1 vector control. 24 h transfection, cells treated treated TNF (50 ng/ml) additional 24 h.
Cell extracts analyzed DNA fragmentation marker apoptosis. â´± â´±â´±, P â¬? 0.05 P â¬? 0.01, respectively, compared CMV
plus Add groups; # ##, P â¬? 0.05 P â¬? 0.01, respectively, compared CMV plus TNF groups. (B) 293T cells H1299 cells transfected treated described  Cell extracts analyzed caspase-3 activation marker apoptosis. (C) 293T H1299
cells transfected pCMV-BRMS1 versus pCMV vector (Control) siRNA-BRMS1 versus siRNA-control indicated. 48 h transfection, cells suspended various lengths time. Cell death measured trypan blue exclusion assays. Western blots siRNA specifically knocks BRMS1 protein expression. â´± â´±â´±, P â¬? 0.05 P â¬? 0.01, respectively, compared CMV siRNA
control time point; #, P â¬? 0.05 compared time zero groups.

                                                                      8693
 8694     LIU ET AL.                                                                                                    MOL. CELL. BIOL.


(28). explanation tumorigenesis           acetylation K310 playing prominent role regulation loss metastasis suppressor function, priming       transcriptional activity RelA/p65 (11, 33). addi- tumor develop distant metastases. Evidence         tion, TNF promote acetylation K310 demon-
shown Fig. 1, BRMS1 mRNA protein                strated (12). Realizing binding 
decreased NSCLC cell lines human lung cancer tissues           main BRMS1 RelA/p65 included K310, wanted compared normal epithelial lung cell line adjacent non-        determine BRMS1 repressing RelA/p65 tran-
cancerous lung tissues.                                               scriptional activity promoting deacetylation lysine
   separate steps required cancer success-         residue. findings indicate BRMS1 completely abol-
fully metastasize migration, invasion, avoidance cell      ishes TNF stimulated acetylation RelA/p65 K310 death apoptosis (17). Prior studies examining putative             deacetylation results dramatic decrease mechanisms BRMS1-mediated suppression metastasis                transactivation potential RelA/p65 TNF treatment demonstrated effect cancer cell invasion properties,       (Fig. 4). observation interesting given TNF, breast cancer melanoma cells overexpressing              interleukin-6 cytokines, released tumor-
BRMS1 modest decrease motility compared               associated macrophages shown stimulate tumor
parental cells (52, 57). studies shown breast      progression NF-â? B-dependent pathways (32). cancer cells BRMS1 restores gap junctional intercellular         data using siRNA knockdown BRMS1 support premise
communication increases mRNA expression phosphor-              cancers lacking BRMS1 likely robust
ylated connexin 43, responsible closing gap          response TNF cytokine-mediated transcriptional
junction communication (39, 53, 62). demonstrated             activation NF-â? B-dependent antiapoptotic gene products, additional mechanism BRMS1                 known promote tumor cell survival.
functions involves ability corepressor modulate           BRMS1 shown associate mSin3a/
NF-â? B-dependent transcription genes known regulate              HDAC complex (42), demonstrate BRMS1 itself func-
cell survival. Casey coworkers reported BRMS1          tions corepressor regulating binding HDAC1 modulate NF-â? B nuclear translocation                 RelA/p65 promoting HDAC1-mediated deacetylation IKKâ?¤-independent inhibition phosphorylation ? B,            RelA/p65. contrast NCoR SMRT nuclear corepres-
cytosolic protein sequesters NF-â? B, preventing          sors, conserved nuclear receptor interaction motif
nuclear translocation (13). hypothesized BRMS1,             BRMS1. addition, classic hydrophobic 
predominantly nuclear chromatin-associated protein,               gions BRMS1 associated core- regulating NF-â? B transcriptional activity.              pressors (29). observation, fact BRMS1 teth-
   present study demonstrates BRMS1 significantly            ers HDAC1 instead HDAC3, provides sharp contrast inhibits NF-â? B-dependent transcription, specifically trans-       described corepressors, NCoR SMRT.
activation potential RelA/p65.  se-             data demonstrate chromatin-associated BRMS1
lective silencing BRMS1 restores expression NF-â? B-          regulates acetyl-K310 RelA/p65 status NF-â? B 
dependent antiapoptotic genes cIAP-2, Bfl-1/A1, BclxL          pendent cIAP-2 Bfl-1/A1 promoters (Fig. 6). HEK 293T NSCLC cells sensitizes cell lines            dismiss role mSin3a potential contribution TNF-induced apoptosis (Fig. 2 7). Previous studies           inhibition RelA/p65-dependent transcription shown antiapoptotic proteins protect cancer cells           concomitant decrease mSin3a chromatin loss
anoikis prolong survival, increasing likeli-       BRMS1. addition, given corepressor function hood survive following invasion            BRMS1, surprising modify
detachment  extracellular matrix (49, 66). regu-         chromatin structure enhanced deacetylation 
lation tumor cell viability cancer cells migrate, invade,   tone tails H3 H4.  noted Fig. 5, vitro detach enter bloodstream key event tumor         coexpression BRMS1 HDAC1 sufficient ef-
metastatic progression.  demonstrated present          ficiently deacetylate RelA/65.  BRMS1 enhances 
study, BRMS1-mediated suppression NF-â? B-dependent               pression endogenous NF-â? B-dependent antiapoptotic genes
tiapoptotic gene expression results proapoptotic state,          promoting HDAC-1-mediated deacetylation RelA/p65
priming tumor TNF-mediated cell death.                        directly chromatin.
   BRMS1 coimmunoprecipitates endogenous                    summary, demonstrate metastasis suppressor
RelA/p65 p50 (Fig. 3).  BRMS1 directly inter-            BRMS1 directly interacts RelA/p65 inhibits trans-
acts C-terminal region RHD RelA/p65                activation potential,  functioning corepressor (amino acids 254 354). functional significance              HDAC1-mediated deacetylation RelA/p65. loss BRMS1 binding region RelA/p65 shown Fig. 3E,         BRMS1 likely affect transcription factors  e., AP1, maximal repression RelA/p65 transactivation po-          STAT, ) regulated HDAC1 involved tential occurs constructs overexpressing binding domain.      cancer cell survival signal transduction pathways. Future stud-
Interestingly, HDAC1 described bind          ies focus upstream events BRMS1 region RelA/p65 (65).                                      regulated, particularly relate ability BRMS1    NF-â? B transcription regulated interactions        decrease tumor cell survival. inhibitor ? B, recent studies identified importance acetylation regulating activity (10, 11, 64).                         ACKNOWLEDGMENTS RelA/p65 subunit NF-â? B acetylated coactiva-            thank Marty W. Mayo (University Virginia) review tors p300, CBP, p/CAF known lysine residues,         manuscript constructive comments.
 VOL. 26, 2006                                                                                                                          BRMS1 NF-â? B                 8695

  study supported grant Commonwealth                           ? B kinase alpha: prerequisite NF-â? B transcription survival. Mol.
Foundation Cancer Research (D.R.J.) NIH Surgery                                 Cell 16:245â€“255.
search Training grant T32 HL007849 (P.W.S.).                                            27.   Hong, S. Y., W. H. Yoon, J. H. Park, S. G. Kang, J. H. Ahn, T. H. Lee.
                                                                                              2000. Involvement NF-â? B binding elements tumor necrosis factor
                                                                                              alpha-, CD40-, Epstein-Barr virus latent membrane protein 1-mediated
                                  REFERENCES                                                  induction cellular inhibitor apoptosis protein 2 gene. J. Biol. Chem.
 1. Aggarwal, B. B. 2004. Nuclear factor-â? B: enemy  Cancer Cell                    275:18022â€“18028.
    6:203â€“208.                                                                          28.   Jemal, , R. Siegel, E. Ward, T. Murray, J. Xu, C. Smigal, M. J. Thun.
 2. Ashburner, B. P., S. D. Westerheide,  S. Baldwin, Jr. 2001. p65                 2006. Cancerstatistics, 2006. CA Cancer J. Clinicians 56:106â€“130.
    (RelA) subunit NF-â? B interacts histone deacetylase (HDAC)               29.   Jepsen, K., M. G. Rosenfeld. 2002. Biological roles mechanistic
    corepressors HDAC1 HDAC2 negatively regulate gene expression.                      actions repressor complexes. J. Cell Sci. 115:689â€“698.
    Mol. Cell. Biol. 21:7065â€“7077.                                                      30.   Jones, D. R., R. M. Broad, L. D. Comeau, S. J. Parsons, M. W. Mayo.
 3. Baeuerle, P.  1998. ? B-NF-â? B structures: interface inflammation              2002. Inhibition nuclear factor â? B chemosensitizes non-small cell lung
    control. Cell 95:729â€“731.                                                                 cancer cytochrome c release caspase activation. J. Thorac.
 4. Baldwin,  S., Jr. 1996. NF-â? B â? B proteins: new discoveries                Cardiovasc. Surg. 123:310â€“317.
    insights. Annu. Rev. Immunol. 14:649â€“683.                                           31.   Jones, D. R., R. M. Broad, L. V. Madrid,  S. Baldwin, Jr., M. W. Mayo.
 5. Balkwill, F. 2002. Tumor necrosis factor tumor promoting factor? Cyto-                 2000. Inhibition NF-â? B sensitizes non-small cell lung cancer cells     kine Growth Factor Rev. 13:135â€“141.                                                       chemotherapy-induced apoptosis. Ann. Thorac. Surg. 70:930â€“937.
 6. Bitterman, K. J., R. M. Anderson, H. Y. Cohen, M. Latorre-Esteves,              32.   Karin, M., F. R. Greten. 2005. NF-â? B: linking inflammation immu-
    D.  Sinclair. 2002. Inhibition silencing accelerated aging nicotin-           nity cancer development progression. Nat. Rev. Immunol. 5:749â€“759.
    amide, putative negative regulator yeast sir2 human SIRT1. J. Biol.        33.   Kiernan, R., V. Bres, R. W. Ng, M. P. Coudart, S. El Messaoudi, C. Sardet,
    Chem. 277:45099â€“45107.                                                                    D. Y. Jin, S. Emiliani, M. Benkirane. 2003. Post-activation turn  7. Bours, V., E. Dejardin, F. Goujon-Letawe, M. P. Merville, V. Cas-                     NF-â? B-dependent transcription regulated acetylation p65. J. Biol.
    tronovo. 1994. NF-â? B transcription factor cancer: high expression              Chem. 278:2758â€“2766.
    NF-â? B- â? B-related proteins tumor cell lines. Biochem. Pharmacol.           34.   Kuo, M. H., C. D. Allis. 1999. vivo cross-linking immunoprecipi-
    47:145â€“149.                                                                               tation studying dynamic protein-DNA associations chromatin envi-
 8. Chakrabarti, S. K., J. C. James, R. G. Mirmira. 2002. Quantitative                    ronment. Methods 19:425â€“433.
    assessment gene targeting vitro vivo pancreatic transcrip-      35.   Laherty, C. D., W. M. Yang, J. M. Sun, J. R. Davie, E. Seto, R. N.
    tion factor, Pdx1. Importance chromatin structure directing promoter                Eisenman. 1997. Histone deacetylases associated mSin3 corepressor
    binding. J. Biol. Chem. 277:13286â€“13293.                                                  mediate mad transcriptional repression. Cell 89:349â€“356.
 9. Chen, C., L. C. Edelstein, C. Gelinas. 2000. Rel/NF-â? B family               36.   Lee, C. W., W. N. Lin, C. C. Lin, S. F. Luo, J. S. Wang, J. Pouyssegur,     directly activates expression apoptosis inhibitor Bcl-xL. Mol. Cell. Biol.         C. M. Yang. 2006. Transcriptional regulation VCAM-1 expression     20:2687â€“2695.                                                                             tumor necrosis factor-alpha human tracheal smooth muscle cells: involve-
10. Chen, L., W. Fischle, E. Verdin, W. C. Greene. 2001. Duration nuclear              ment MAPKs, NF-â? B, p300, histone acetylation. J. Cell Physiol.
    NF-â? B action regulated reversible acetylation. Science 293:1653â€“1657.                  207:174â€“186.
11. Chen, L. F., Y. Mu, W. C. Greene. 2002. Acetylation RelA discrete         37.   Lee, D. K., J. E. Kang, H. J. Park, M. H. Kim, T. H. Yim, J. M. Kim, M. K.
    sites regulates distinct nuclear functions NF-â? B. EMBO J. 21:6539â€“6548.                Heo, K. Y. Kim, H. J. Kwon, M. W. Hur. 2005. FBI-1 enhances tran-
12. Chen, L. F., S.  Williams, Y. Mu, H. Nakano, J. M. Duerr, L. Buckbinder,                scription nuclear factor-â? B (NF-â? B)-responsive E-selectin gene     W. C. Greene. 2005. NF-â? B RelA phosphorylation regulates RelA acet-                   nuclear localization p65 subunit NF-â? B. J. Biol. Chem. 280:27783â€“
    ylation. Mol. Cell. Biol. 25:7966â€“7975.                                                   27791.
13. Cicek, M., R. Fukuyama, D. R. Welch, N. Sizemore, G. Casey. 2005.
                                                                                        38.   Liu, Y., C. E. Denlinger, B. K. Rundall, P. W. Smith, D. R. Jones. 21
    Breast cancer metastasis suppressor 1 inhibits gene expression targeting
                                                                                              August 2006, posting date. SAHA induces Akt-mediated phosphorylation     nuclear factor-â? B activity. Cancer Res. 65:3586â€“3595.
                                                                                              p300 promotes acetylation transcriptional activation RelA/p65.
14. Dejardin, E., G. Bonizzi,  Bellahcene, V. Castronovo, M. P. Merville,                                                                                               J. Biol. Chem. [Online.] doi: 10.1074/jbc.M604478200.
    V. Bours. 1995. Highly-expressed p100/p52 (NFKB2) sequesters NF-
                                                                                        39.   Locke, D. 1998. Gap junctions normal neoplastic mammary gland.
    â? B-related proteins cytoplasm human breast cancer cells. Oncogene
                                                                                              J. Pathol. 186:343â€“349.
    11:1835â€“1841.
                                                                                        40.   Marks, P., R.  Rifkind, V. M. Richon, R. Breslow, T. Miller, W. K.
15. Dâ€™Souza, B. N., L. C. Edelstein, P. M. Pegman, S. M. Smith, S. T. Loughran,
                                                                                              Kelly. 2001. Histone deacetylases cancer: causes therapies. Nat.
     Clarke,  Mehl, M. Rowe, C. Gelinas, D. Walls. 2004. Nuclear factor
                                                                                              Rev. Cancer 1:194â€“202.
    â? B-dependent activation antiapoptotic bfl-1 gene Epstein-Barr
    virus latent membrane protein 1 activated CD40 receptor. J. Virol.              41.   Mayo, M. W., C. E. Denlinger, R. M. Broad, F. Yeung, E. T. Reilly, Y. Shi,
    78:1800â€“1816.                                                                             D. R. Jones. 2003. Ineffectiveness histone deacetylase inhibitors 16. Duffey, D. C.,  Chen, G. Dong, F. G. Ondrey, J. S. Wolf, K. Brown, U.                   induce apoptosis involves transcriptional activation NF-â? B     Siebenlist, C. Van Waes. 1999. Expression dominant-negative mu-                  Akt pathway. J. Biol. Chem. 278:18980â€“18989.
    tant inhibitor-â? Balpha nuclear factor-â? B human head neck squa-            42.   Meehan, W. J., R. S. Samant, J. E. Hopper, M. J. Carrozza, L.  Shevde,
    mous cell carcinoma inhibits survival, proinflammatory cytokine expression,               J. L. Workman, K.  Eckert, M. F. Verderame, D. R. Welch. 2004.
    tumor growth vivo. Cancer Res. 59:3468â€“3474.                                       Breast cancer metastasis suppressor 1 (BRMS1) forms complexes ret-
17. Fidler,  J. 1995. Critical factors biology human cancer metastasis.           inoblastoma-binding protein 1 (RBP1) mSin3 histone deacetylase
     Surgeon 61:1065â€“1066.                                                                 complex represses transcription. J. Biol. Chem. 279:1562â€“1569.
18. Fischle, W., S. Emiliani, M. J. Hendzel, T. Nagase, N. Nomura, W. Voelter,          43.   Meehan, W. J., D. R. Welch. 2003. Breast cancer metastasis suppressor
    E. Verdin. 1999. new family human histone deacetylases related                1: update. Clin. Exp. Metastasis 20:45â€“50.
    Saccharomyces cerevisiae HDA1p. J. Biol. Chem. 274:11713â€“11720.                     44.   Mountain, C. F. 1997. Revisions international staging lung
19. Frisch, S. M., H. Francis. 1994. Disruption epithelial cell-matrix                 cancer. Chest 111:1710â€“1717.
    interactions induces apoptosis. J. Cell Biol. 124:619â€“626.                          45.   Nagy, L., H. Y. Kao, D. Chakravarti, R. J. Lin, C.  Hassig, D. E. Ayer, S. L.
20. Gerritsen, M. E.,  J. Williams,  S. Neish, S. Moore, Y. Shi, T.                   Schreiber, R. M. Evans. 1997. Nuclear receptor repression mediated     Collins. 1997. CREB-binding protein/p300 transcriptional coactivators              complex containing S